Summit Therapeutics (SMMT) Shares Outstanding (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Shares Outstanding (Entity) data on file, last reported at $793.1 million in Q2 2026.

• Quarterly Shares Outstanding (Entity) rose 6.77% year-over-year to $793.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $793.1 million (up 6.77% YoY) and the FY2025 annual result came in at $775.4 million, up 5.12% from the prior year.
• Shares Outstanding (Entity) rose to $793.1 million in Q2 2026, from $776.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $793.1 million in Q2 2026 to a low of $98.1 million in Q1 2022.
• A 5-year average of $583.6 million and a median of $713.1 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) grew 0.79% — and 2023, when it soared 611.04%.
• Tracing SMMT's Shares Outstanding (Entity) over 5 years: stood at $211.1 million in 2022, then soared by 232.4% to $701.7 million in 2023, then rose by 5.13% to $737.6 million in 2024, then gained by 5.12% to $775.4 million in 2025, then climbed by 2.29% to $793.1 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $793.1 million (Q2 2026), $776.0 million (Q1 2026), and $775.4 million (Q4 2025), per Business Quant data.